张家界推出全景无人机观光体验 科技赋能低空文旅新业态 中新网张家界12月30日电 (记者 杨华峰)30日，一场以全景无人机为载体的观光体验活动在湖南张家界 精彩启幕。游客可亲手操控无人机，以"第一视角"360度穿梭于奇峰云海之间，化身电影《阿凡达》中 的角色，畅享自由"空中观景"的震撼体验。 外籍游客在专业飞手的指导下佩戴VR眼镜，实时接收无人机回传的8K全景高清画面。记者 杨华峰 摄 活动现场，游客在专业飞手的指导下佩戴 VR眼镜，实时接收无人机回传的8K全景高清画面：只需轻轻 转动头部，就能自由切换观景视角，将张家界的山川奇景尽收眼底；配合"虚拟座舱"功能，更能沉浸式 感受"骑龙飞行"的奇幻视觉体验。 "就像自己长了翅膀在天上飞，从未以这样的视角看过风景。"一位体验完的游客难掩兴奋地赞叹。据介 绍，该项目借助前沿数字技术，将动画元素巧妙融入真实峰林景观，营造出如《阿凡达》中"潘多拉星 球"般的梦幻航行效果。 此次投入应用的"影翎 Antigravity"无人机，是首款支持8K实时全景图传的无人机产品。它依托智能航迹 规划等核心技术，能够在张家界复杂的山地环境中实现安全、稳定飞行，为游客的沉浸式体验提供了可 ...

Group 1: Investment Trends - The investment in the robotics sector remains strong, with significant funding rounds reported in the past week [1] - Medical device investments are also gaining traction, showcasing a robust performance in the healthcare sector [1] - A total of 22 financing events occurred in the domestic primary market from September 22 to September 28, with a total scale of approximately 3.366 billion RMB [1] Group 2: Sector-Specific Financing - The advanced manufacturing sector completed 9 financing rounds, raising over 540 million RMB, while the robotics sector had 5 financing rounds totaling approximately 1.469 billion RMB [3] - The healthcare sector saw significant investments, including a 63 million USD financing round for Haobo Pharmaceutical [8][9] Group 3: Regional Distribution of Financing - The majority of financing events were concentrated in Jiangsu, Guangdong, and Zhejiang provinces, with Jiangsu leading with 17 cases [4] Group 4: Active Investment Institutions - Active investment institutions included Eagle Investment and PwC Capital, each completing 2 financing rounds primarily in the technology and manufacturing sectors [6] Group 5: Notable Company Financing - Suzhou Laisai Intelligent Technology completed a multi-million RMB Pre-B financing round led by Eagle Investment's Star Fund and Xieli Investment [13][14] - Xingmai Innovation secured 1 billion RMB in A+ round financing, led exclusively by Meituan Longzhu [8] - Aifei Biopharmaceutical announced nearly 300 million RMB in B3 financing, aimed at accelerating clinical research for innovative cancer drugs [12]